Last updated: August 23, 2026
Belcher Pharmaceuticals, LLC v. Hospira, Inc. concerned Hospira’s abbreviated new drug application for a generic epinephrine injection product and Belcher’s U.S. Patent No. 9,283,197. The District of Delaware held the asserted claims invalid for obviousness and unenforceable for inequitable conduct. The Federal Circuit affirmed the judgment in 2021. The decision removed the principal patent barrier to Hospira’s generic epinephrine product.[1][2]
What was the Belcher Pharmaceuticals v. Hospira case about?
Belcher marketed Adrenalin, an epinephrine injection product. Hospira filed an ANDA seeking FDA approval for a competing epinephrine injection product. Belcher sued under the Hatch-Waxman framework, alleging that Hospira’s ANDA product would infringe the ’197 patent.
The case was filed in the U.S. District Court for the District of Delaware as Case No. 1:17-cv-00775. The asserted patent covered an epinephrine formulation with specified pH and stability characteristics.
| Case element |
Detail |
| Plaintiff |
Belcher Pharmaceuticals, LLC |
| Defendant |
Hospira, Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:17-cv-00775 |
| Federal Circuit appeal |
Belcher Pharmaceuticals, LLC v. Hospira, Inc., 11 F.4th 1345 |
| Reference product |
Adrenalin, epinephrine injection |
| ANDA sponsor |
Hospira |
| Principal patent |
U.S. Patent No. 9,283,197 |
| Main issues |
Infringement, obviousness, inequitable conduct |
| Final appellate result |
Judgment for Hospira affirmed |
What patent protected Belcher’s Adrenalin epinephrine product?
The primary patent was U.S. Patent No. 9,283,197, titled “Epinephrine Formulations.” The patent issued on March 15, 2016, from an application claiming priority to a 2012 provisional filing. Its expected expiration date was in 2033, subject to any applicable patent-term adjustment or regulatory extension.
The challenged claims focused on an epinephrine formulation having:
- A defined epinephrine concentration;
- A pH range of approximately 2.8 to 3.3;
- Low degradation over time; and
- Restrictions concerning sulfite or related stabilizing components.
The patent’s commercial importance came from its attempt to protect a formulation distinction rather than the epinephrine molecule itself. Epinephrine has been used clinically for decades and was not a new chemical entity. The commercial patent position therefore depended on formulation, stability, and manufacturing distinctions.
What technical features did the asserted claims cover?
The asserted formulation claims addressed the stability of epinephrine in an injectable product. Epinephrine is susceptible to degradation, and formulation pH can affect color change, oxidation, and potency retention.
Belcher argued that the claimed combination of pH, degradation limits, and composition restrictions was not disclosed or suggested by the prior art. Hospira argued that the formulation parameters were within the routine skill of pharmaceutical formulators and that the prior art provided a reason to optimize pH and stability.
The Federal Circuit agreed with the district court that the claimed formulation was obvious when viewed against the relevant prior art and the ordinary skill of pharmaceutical scientists.[2]
When did the Belcher patent lose exclusivity?
The ’197 patent lost practical exclusivity when the courts held the asserted claims invalid and unenforceable. The patent’s nominal 2033 expiration date no longer controlled the ANDA dispute after the final judgment.
| Exclusivity component |
Timing or status |
| Patent filing priority |
2012 |
| Patent issuance |
March 15, 2016 |
| Nominal patent expiration |
Approximately 2033 |
| Belcher complaint |
2017 |
| District court judgment |
Judgment entered for Hospira after findings of invalidity and unenforceability |
| Federal Circuit decision |
2021 |
| Practical patent barrier |
Removed by final judgment |
The Hatch-Waxman litigation created a statutory approval stay while the case proceeded. That stay did not preserve the patent after invalidity and unenforceability findings.
What did the court decide on obviousness?
The district court concluded that the asserted claims were obvious. The Federal Circuit affirmed.
The courts evaluated whether the prior art provided a sufficient basis to formulate epinephrine within the claimed pH range and achieve the claimed stability characteristics. The analysis considered:
- Prior disclosures concerning epinephrine formulations;
- Known pH and stability relationships;
- Routine formulation experimentation;
- The motivation to improve stability and product shelf life; and
- The absence of a persuasive unexpected-results showing tied to the full claim scope.
The court rejected Belcher’s position that the claimed pH range represented a non-obvious technical breakthrough. The Federal Circuit held that the district court had adequate support for its obviousness determination.
The decision is relevant to pharmaceutical patent prosecution because it treats narrow formulation ranges as vulnerable when the claimed parameters are optimization targets already recognized in the art. A formulation patent is more exposed when:
- The prior art identifies the same stability problem;
- The claimed range is the result of routine testing;
- The specification does not establish a meaningful technical difference across the entire claim scope; or
- The asserted unexpected results are not commensurate with the claims.
Why did the court find inequitable conduct?
The district court also found the ’197 patent unenforceable for inequitable conduct. The finding concerned the withholding of material information from the U.S. Patent and Trademark Office, including prior art and information relating to the development and regulatory history of the formulation.
The Federal Circuit affirmed the inequitable-conduct determination. The court concluded that the evidence supported a finding that the relevant individual had knowledge of material information and withheld it with the specific intent to deceive the Patent Office.[2]
Inequitable conduct is separate from invalidity. Obviousness eliminates the patent claims as a matter of patentability. Inequitable conduct prevents enforcement of the patent even if a claim otherwise survived validity review.
The case is significant because the court applied inequitable-conduct principles to formulation patent prosecution. Pharmaceutical companies prosecuting formulation claims should maintain a documented prior-art review, identify regulatory and development materials that may bear on patentability, and ensure that known material references are disclosed before issuance.
What was the Paragraph IV challenge in this case?
Hospira’s ANDA was the basis for a Hatch-Waxman infringement action under 35 U.S.C. § 271(e)(2). The litigation functioned as a Paragraph IV dispute because Hospira challenged Belcher’s patent position rather than accepting that the patent would block approval.
A Paragraph IV ANDA challenge typically requires the generic applicant to assert that:
- The patent is invalid;
- The patent is unenforceable;
- The ANDA product does not infringe; or
- The patent is not eligible to block approval.
The Belcher case ultimately turned on patent validity and enforceability. The Federal Circuit’s decision did not create a delayed generic-entry framework based on a settlement. It affirmed the judgment that the asserted patent could not be enforced against Hospira.
What was the Orange Book status of the Belcher epinephrine patent?
The ’197 patent was associated with Belcher’s Adrenalin epinephrine injection product and was listed in the FDA’s Orange Book at the time of the litigation. The listing provided the regulatory basis for Belcher’s Hatch-Waxman lawsuit after Hospira submitted its ANDA.[3]
| Orange Book issue |
Analysis |
| Listed product |
Adrenalin epinephrine injection |
| Listed patent |
U.S. Patent No. 9,283,197 |
| Patent type |
Drug-product formulation patent |
| NCE exclusivity |
Not the principal issue because epinephrine was an established active ingredient |
| Regulatory dispute |
ANDA approval and patent certification |
| Litigation result |
Patent claims held invalid and unenforceable |
Orange Book listing does not establish patent validity. It permits the listed patent holder to invoke the Hatch-Waxman litigation process. The Belcher decision illustrates the commercial risk of relying on a listed formulation patent that has not been tested against prior-art and inequitable-conduct challenges.
Which companies challenged the Belcher patent?
Hospira was the defendant and ANDA challenger in the reported case. Hospira operated within Pfizer’s pharmaceutical business during the relevant period, but the named litigation party was Hospira, Inc.
The public appellate decision does not establish a separate multi-defendant patent campaign involving several generic companies. The dispute principally addressed Belcher’s patent against Hospira’s ANDA product.
Did Belcher and Hospira settle the litigation?
The reported appellate record reflects a merits judgment rather than a publicly reported settlement. The Federal Circuit affirmed the district court’s rulings of invalidity and unenforceability.
No settlement-based generic launch date governed the outcome. Hospira’s position prevailed through litigation.
How strong was Belcher’s patent estate?
Belcher’s patent estate was commercially focused but ultimately weak against a validity challenge.
Strengths
- The patent targeted a specific injectable formulation;
- It was listed in the Orange Book;
- It created a Hatch-Waxman litigation trigger;
- The formulation claims had a nominal term extending into the 2030s.
Weaknesses
- The active ingredient was old and broadly available;
- The claimed pH and stability parameters were vulnerable to an optimization-based obviousness argument;
- The record supported an inequitable-conduct finding;
- The patent appears to have been the central barrier at issue rather than one element of a broad, redundant patent portfolio.
The principal lesson for investors and licensing counterparties is that nominal patent life overstated the remaining enforceable exclusivity. Once the asserted claims were invalidated and held unenforceable, the patent’s commercial value against Hospira was effectively eliminated.
What generic launch risks existed after the judgment?
The judgment materially reduced generic-entry risk for Hospira because the principal patent barrier no longer supported an injunction or delayed FDA approval.
| Launch factor |
Effect after final judgment |
| Patent validity |
Claims invalid |
| Patent enforceability |
Patent held unenforceable |
| Injunction risk |
Substantially reduced |
| Regulatory stay |
No longer a durable barrier |
| Formulation patent risk |
Reduced for the accused product |
| Settlement delay |
Not applicable on the reported record |
| Remaining barriers |
FDA approval, manufacturing readiness, labeling, and commercial strategy |
The decision did not guarantee a commercial launch. FDA approval, manufacturing capacity, supply contracts, pharmacovigilance, product labeling, and market economics remained separate considerations. The patent ruling removed the principal litigation-based obstacle.
How does this case compare with typical pharmaceutical formulation litigation?
Belcher v. Hospira is a high-risk outcome for a branded company relying on a narrow formulation patent. Formulation patents can provide meaningful exclusivity when they claim a technically difficult composition, a non-obvious manufacturing process, or a demonstrated clinical or stability advantage. They are more vulnerable when the claims capture routine pH adjustment or predictable stability optimization.
The case also differs from disputes resolved through a settlement with a negotiated launch date. Here, the appellate decision confirmed that Belcher could not enforce the asserted patent against Hospira.
What are the commercial implications for epinephrine products?
Epinephrine is a mature active ingredient with established clinical use and multiple potential suppliers. The relevant commercial value lies in:
- FDA-approved dosage form and presentation;
- Injectable stability and shelf life;
- Reliable sterile manufacturing;
- Hospital and emergency-care distribution;
- Product labeling and substitution status; and
- Supply continuity.
Belcher’s product-specific revenue exposure was not quantified in the judicial opinions. The litigation record supports a legal conclusion, not a standalone revenue forecast. The invalidity ruling reduced the ability to preserve premium pricing through the ’197 patent and increased the competitive relevance of manufacturing execution and distribution.
Key Takeaways
- Belcher sued Hospira over an ANDA for a competing epinephrine injection product.
- The principal asserted patent was U.S. Patent No. 9,283,197.
- The patent covered formulation parameters including pH and stability characteristics.
- The District of Delaware held the asserted claims obvious and the patent unenforceable for inequitable conduct.
- The Federal Circuit affirmed in 2021.
- The patent’s nominal expiration around 2033 did not provide practical exclusivity after the final judgment.
- The case did not end in a publicly reported settlement.
- The decision reduced Hospira’s patent-based generic launch risk and weakened Belcher’s formulation-based exclusivity position.
FAQs About Belcher Pharmaceuticals v. Hospira
What drug was involved in Belcher v. Hospira?
The dispute involved epinephrine injection, including Belcher’s Adrenalin product and Hospira’s proposed generic epinephrine injection.
What patent number did Belcher assert against Hospira?
Belcher principally asserted U.S. Patent No. 9,283,197, covering epinephrine formulation characteristics.
Did Hospira win the Belcher patent case?
Yes. Hospira prevailed after the district court held the patent claims invalid and unenforceable. The Federal Circuit affirmed.
Was the Belcher patent invalidated for anticipation?
The reported appellate decision affirmed invalidity based on obviousness. The principal holding was that the claimed formulation would have been obvious in view of the prior art.
Does the case affect biosimilar competition?
No. Epinephrine is a small-molecule active ingredient, so the dispute involved an ANDA and generic competition rather than a biologics license application or biosimilar pathway.
Sources
- Belcher Pharmaceuticals, LLC v. Hospira, Inc., No. 1:17-cv-00775, U.S. District Court for the District of Delaware.
- Belcher Pharmaceuticals, LLC v. Hospira, Inc., 11 F.4th 1345 (Fed. Cir. 2021).
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
